Mounjaro Cost: $1,112 US vs ~$147 in India

Key Takeaways

~$1,112 list here, ~$147 in India — from the maker itself. Eli Lilly launched the Mounjaro pen in India in August 2025 at about $160/month for the starting dose (Reuters); it was about $147 by December 2025. US list is dose-flat at ~$1,112. A gap of more than 7× at the starting dose.
The maker's own prices undercut the list. Lilly's US self-pay program sells the same molecule (as Zepbound) for $299–$449/month with on-time refills. Cost studies on the rival molecule (semaglutide) put a profitable price at a few dollars to about $40 a month. It's the system, not the chemistry.
Medicare's July 2026 pilot is real — and conditional. $50 copay for weight-loss use, a first. But temporary (through end-2027), and for tirzepatide it covers only the Zepbound KwikPen — not Mounjaro. Only about a third of the biggest employers cover these drugs for weight loss (KFF 2026), and over 1 in 4 insured users have paid full cost (KFF 2025).
"Just order it abroad" has three problems. FDA says personal importation is illegal in most circumstances, and packages can be seized; counterfeit Ozempic pens have reached the regulated supply chain in the US, UK and Brazil; and the FDA closed the compounded path in 2025, a move the courts declined to block.
The gap is real — and bending. The US spent $71.7B on GLP-1 drugs in 2023, before rebates, but self-pay prices from $299, the Medicare pilot, and a rival's announced list-price cuts for 2027 (about 35% for Ozempic and 50% for Wegovy) are moving prices. Never autopay list.

Cost Comparison (2026)

Figures from Reuters' coverage of the India launch, Japan's NHI listing, UK reimbursement prices, KFF coverage surveys, CMS, peer-reviewed studies, and the maker's own published prices. Where a number is reported or still changing, we say so.

Bar chart of the monthly price of Mounjaro by country, October 2026: Japan $37–221 by dose, India $147 at the starting dose, UK $178–440 by dose, Switzerland $271–470 per pen, Netherlands $198–485 per pen, US list price $1,112 at every dose. — One month or one pen (four weekly doses). Where a country prices by dose, the bar runs from the lowest to the highest dose. US: Eli Lilly list price per 28 days, the same at every dose. Japan: national health insurance price list (Aug 2026). India: starting dose (Reuters, Dec 2025). UK: Lilly list prices (Community Pharmacy England, Sept 2025). Switzerland: public price, BAG Spezialitätenliste. Netherlands: average pharmacy price, Zorginstituut. Germany is not shown: the official figure is €807.84 for a pack of three 5 mg pens. USD at ECB rates of October 26, 2026. Made by Wellness Vision from the values in the table below.

Country	Price for one month or one pen	In US dollars	What a patient typically pays
🇺🇸 United States (list)	$1,112.16 per 28 days, every dose	$1,112	Depends on insurance
🇮🇳 India	about ₹13,125, starting dose (Dec 2025)	$147	—
🇯🇵 Japan	national insurance price, by dose (type 2 diabetes only)	$37–$221	—
🇬🇧 United Kingdom	£133–£330 a month by dose (Lilly list price, 2025)	$178–$440	—
🇨🇭 Switzerland	CHF 223.80–388.40 per pen (four weekly doses)	$271–$470	Reimbursed for type 2 diabetes and, with prior approval, for adult obesity (up to three years)
🇳🇱 Netherlands	€176.58–€433.82 per KwikPen (average pharmacy price)	$198–$485	Reimbursed for type 2 diabetes only
🇩🇪 Germany	€807.84 for a pack of three 5 mg pens (G-BA)	—	Insurance pays only for type 2 diabetes; for weight loss patients pay the full price themselves

Conversions to US dollars at ECB rates of October 26, 2026, as in the chart. “—”: the article gives no figure for this.

Market	Figure	Context	Source
United States	~$1,112/month (list)	US list price is dose-flat — every strength costs the same ($1,112.16 per 28 days); pharmacies pay about $1,077 for four pens (CMS NADAC, Oct 2026). Lilly sells the same molecule as Zepbound to self-pay patients for $299–$449/month with on-time refills ($499–$699 otherwise). The US spent $71.7B on GLP-1 drugs in 2023, before rebates.	Lilly list price (2026) · CMS NADAC · LillyDirect (Zepbound) · Tsipas et al., JAMA Netw Open 2025
India	~$147/month (starting dose)	Lilly launched the KwikPen in India in August 2025 at ₹14,000 (~$160) for the starting dose; after a tax cut it sold for about ₹13,125 (~$147) by December 2025 — same tirzepatide, priced by the maker. A gap of more than 7× at the starting dose (US list is dose-flat, India's rises with dose).	Reuters (Aug & Dec 2025)
Japan · UK	~$37–$221 · £133–£330 / month by dose	Japan's national insurance lists ~$37–221 a month by dose after a 25% government price cut on Aug 1, 2026 (type 2 diabetes only). Lilly's UK list price runs £133–330 a month after it raised prices by up to 170% in September 2025. Japan sets one national price; in the UK these are the maker's list prices.	MHLW NHI price list (Aug 2026) · Community Pharmacy England (Sept 2025)
Germany	€807.84 (5 mg) · €1,126.44 (10 mg) per pack	A Federal Joint Committee (G-BA) decision of August 20, 2026 lists Mounjaro at a pharmacy price of €807.84 for a pack of three 5 mg pens and €1,126.44 for three 10 mg pens (Lauer-Taxe, June 15, 2026), and puts the annual cost to statutory insurance at €3,308–€4,615 per patient after mandatory rebates. Insurance pays only for type 2 diabetes; for weight loss patients pay the full price themselves. Trade press had reported €206–€489 per monthly pack in 2025.	G-BA decision (Aug 2026) · APOTHEKE ADHOC (Feb 2025)
Switzerland · Netherlands	CHF 223.80–388.40 · €176.58–433.82 per pen	Switzerland's official list prices one Mounjaro pen — four weekly doses — at CHF 223.80 (2.5 and 5 mg), CHF 303.25 (7.5 and 10 mg) and CHF 388.40 (12.5 and 15 mg), public price including VAT; a confidential rebate goes back to insurers. It is reimbursed for type 2 diabetes and, with prior approval, for adult obesity (for up to three years). The Dutch Zorginstituut lists €176.58–€433.82 per KwikPen (average pharmacy price), reimbursed for type 2 diabetes only. Austria's reimbursement code does not list Mounjaro.	BAG Spezialitätenliste · Zorginstituut (Oct 2026) · Dachverband EKO (Nov 2026)
The catch — coverage	Conditional	A Medicare pilot began July 1, 2026: $50 copay for weight-loss use — a first, but temporary (through end-2027). It covers Zepbound only in its KwikPen form, not Mounjaro. Only about 1 in 3 of the largest employers cover these drugs for weight loss (2026); over 1 in 4 insured users have paid full cost.	CMS Medicare GLP-1 Bridge · KFF EHBS 2026 · KFF poll (Nov 2025)

We compare what the drug costs, not what anyone should take, switch, or import. Treatment decisions belong with you and a licensed prescriber.

Critical Considerations

Relief arrived in July 2026 — read the fine print

On July 1, 2026, a Medicare pilot began covering tirzepatide (as the Zepbound KwikPen) and semaglutide for weight loss at a $50 copay — the first time Medicare has covered these drugs for weight loss at all. An honest comparison says that loudly. It also says the rest: the pilot is scheduled only through the end of 2027, for tirzepatide it covers only the Zepbound KwikPen, and it does nothing for the employer-coverage gap, where only about one in three of America's largest employers cover these drugs for weight loss (KFF 2026) and more than 1 in 4 insured users have paid the full cost themselves (KFF 2025).

The maker's own prices tell the story

Eli Lilly sells the same molecule three ways: ~$1,112 list in the US, $299–$449 through its own US self-pay program (sold as Zepbound), and ~$160 a month at its official India launch. When one company's own price list spans a more than 7-fold range for the same drug, the list price is a choice, not a cost. Peer-reviewed cost studies on semaglutide, the rival molecule, put a profitable price at a few dollars a month at diabetes doses and about $40 at the weight-loss dose.

The honest math on "just buy it abroad"

Personal importation isn't a legal right — the FDA says it is illegal in most circumstances, and packages can be seized. The counterfeit problem is not hypothetical: fake Ozempic pens have turned up inside the regulated supply chain in the US, UK and Brazil. Separately, the FDA had received more than 1,700 adverse-event reports tied to compounded semaglutide and tirzepatide by May 2026. And the cheap compounded workaround closed in 2025, when the FDA declared the shortages over and a federal court declined to block that decision. Before paying list, the safe move is knowing every legitimate channel — the maker's cash program, the new Medicare pilot, and plan-by-plan coverage checks.

Frequently Asked Questions

How much does Mounjaro cost in the US versus other countries?

The US list price is about $1,112 a month, and it's dose-flat — every strength costs the same. Eli Lilly launched the same pen in India in August 2025 at roughly $160 a month for the starting dose (Reuters), later about $147. Japan's national insurance lists it at about $37–221 a month depending on dose after a 25% price cut in August 2026, and Lilly's UK list price runs £133–330 after increases of up to 170% in September 2025. Same tirzepatide, same maker.

Isn't Mounjaro just expensive to make?

The maker's own pricing suggests otherwise: Lilly sells the same molecule, as Zepbound, to self-pay Americans for $299–$449 a month with on-time refills — far under the ~$1,112 list. Peer-reviewed cost studies on semaglutide, the rival molecule, estimate it could be made and sold profitably for a few dollars a month at diabetes doses (Barber et al., 2024) and about $40 a month at the weight-loss dose (Levi et al., 2023). The list price reflects the pricing system, not the chemistry.

Does insurance cover Mounjaro or Zepbound for weight loss now?

Conditionally. On July 1, 2026 a Medicare pilot began covering weight-loss drugs at a $50 copay — the first time ever. But it's temporary (scheduled through the end of 2027), and for tirzepatide it covers only Zepbound in its KwikPen form — Mounjaro itself is not included. Outside Medicare, only about one in three of America's largest employers cover these drugs for weight loss (KFF 2026), and more than 1 in 4 insured users report paying the full cost themselves (KFF).

Do other countries get a weaker version of the drug?

No — it's the same tirzepatide from the same manufacturer. India's launch was run by Eli Lilly itself. The structural difference is that some countries, like Japan, set one national price; in the US, list prices are high and the discounts insurers negotiate are confidential, so uninsured and cash-pay patients feel the list price most.

Can Americans just order Mounjaro from abroad?

It's rarely the clean shortcut it sounds like. The FDA says importing prescription drugs for personal use is illegal in most circumstances; it sometimes allows up to a 3-month supply, but mainly when no effective treatment is available in the US — not the case here — and packages can be seized. Counterfeit Ozempic pens have been found inside the regulated supply chain in the US, UK and Brazil (WHO, FDA). And the compounded-copy workaround closed in 2025, when the FDA declared the shortages over and a federal court declined to block it.

How many people struggle to afford GLP-1 drugs?

More than half of users say affording them is difficult, and about 1 in 7 stopped taking them because of cost (KFF). Paying Lilly's $449 self-pay price for Zepbound maintenance doses works out to roughly $5,400 a year for one prescription — presented here strictly as cost data, not guidance. Treatment decisions belong with a licensed prescriber.

Sources

Wellness Vision Editorial Policy

Wellness Vision does not sell medication, book trips, or receive referrals of any kind. The data comes from the public sources cited above. This is a cost comparison, not medical advice — nothing here tells anyone to start, stop, switch, or import a medication.

📋 Or get the free Medical Travel Cost Checklist — no email →

View provenance manifest for this video →

You shouldn't have to go broke to feel whole.

Mounjaro: $1,112 Here, ~$147 in India — Same Maker